Numerous signaling pathways, such as the PI3K/Akt, Notch-1, JAK/STAT, Wnt, and TGF-β, have been shown to play key roles in NSCLC resistance to chemotherapeutic agents [7–12]. Here, AKT1 is linked to non-small cell lung carcinoma.